Association of Supranormal Left Ventricular Function With Major Adverse Cardiovascular Events: A Systematic Review of

Abdul Rahim1, Muhammad Umer Riaz Gondal2, Farman Ali3

  • 1From the Department of Cardiology, Saidu Teaching Hospital, Swat, Pakistan.

Cardiology in Review
|September 5, 2024
PubMed

Insights

Supranormal left ventricular ejection fraction (snLVEF) is linked to higher risks of major adverse cardiovascular events (MACE), especially in women. Further research is needed to understand its role in heart failure (HF) prognosis.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Prognostics

Background:

  • Supranormal left ventricular ejection fraction (snLVEF) is increasingly recognized in cardiovascular disease.
  • Its prognostic significance, particularly in heart failure (HF), requires further elucidation.
  • Understanding snLVEF is crucial for refining risk stratification and management strategies.

Purpose of the Study:

  • To systematically review and assess the prognostic implications of snLVEF in cardiovascular disease, focusing on heart failure.
  • To explore the association between snLVEF and major adverse cardiovascular events (MACE).
  • To identify potential mechanisms linking snLVEF to adverse outcomes.

Main Methods:

  • Comprehensive systematic search of electronic databases for relevant studies.
  • Inclusion of studies using diverse imaging modalities (echocardiography, PET, CT, CMR).
  • Rigorous data extraction and quality assessment based on predefined criteria.

Main Results:

  • Several studies indicate an elevated risk of MACE, including HF hospitalization and stroke, in patients with snLVEF.
  • This increased risk appears particularly pronounced in women, suggesting a potential U-shaped mortality curve.
  • Proposed mechanisms include coronary microvascular dysfunction and autonomic dysregulation, though findings vary across studies.

Conclusions:

  • snLVEF is associated with an increased risk of MACE, especially in women.
  • Prognostic implications of snLVEF may differ among heart failure phenotypes and comorbidities.
  • Tailored risk assessment and management are essential for patients with snLVEF in the context of HF.

Related Concept Videos